作者: Anatoly Kreinin , Serah Lisson , Elimelech Nesher , Jenny Schneider , Josef Bergman
DOI: 10.1371/JOURNAL.PONE.0127643
关键词:
摘要: Though the role of brain derived neurotrophic factor (BDNF) as a marker for major depressive disorder (MDD) and antidepressant efficacy has been widely studied, BDNF in distinct groups patients remains unclear. We evaluated diagnostic value disease severity measured by HAM-D scores antidepressants among MDD patients. Fifty-one who met DSM-IV criteria were prescribed 38 controls participated this study. serum was at baseline, 1st, 2nd 8th treatment weeks. Depression using Hamilton Rating Scale (HAM-D). polymorphism rs6265 (val66met) genotyped. found positive correlation between blood levels depression only untreated women with severe (HAM-D>24). Serum lower compared to control group. Antidepressants increased reduced between-group differences after two weeks treatment. No correlations observed polymorphism, severity, duration illness, age levels. Further supporting pathology MDD, we suggest that it should not be used universal biomarker diagnosis general population. However, assessment progression individual